We also demonstrated that anti-PD-L1 and anti-VEGFR2 therapy can increase the secretion of IFN-γ, GZMB, and perforin by immune cells and reprogram the TME of GBM, thereby promoting the cytotoxic effects of CD8+ T cells (Fig. 7G). The gene discussed is CD8A; the disease is glioblastoma.